Bluestein R H & Company Trimmed Apple (AAPL) Stake; Cumberland Pharmaceuticals (CPIX) Shorts Down By 0.49%

January 14, 2018 - By Adrian Mccoy

Bluestein R H & Company decreased Apple Inc (AAPL) stake by 1.11% reported in 2017Q3 SEC filing. Bluestein R H & Company sold 6,070 shares as Apple Inc (AAPL)’s stock rose 12.78%. The Bluestein R H & Company holds 540,758 shares with $83.34M value, down from 546,828 last quarter. Apple Inc now has $900.87 billion valuation. The stock increased 1.03% or $1.81 during the last trading session, reaching $177.09. About 25.42 million shares traded. Apple Inc. (NASDAQ:AAPL) has risen 62.48% since January 14, 2017 and is uptrending. It has outperformed by 45.78% the S&P500.

Cumberland Pharmaceuticals Incorporated (NASDAQ:CPIX) had a decrease of 0.49% in short interest. CPIX’s SI was 121,500 shares in January as released by FINRA. Its down 0.49% from 122,100 shares previously. With 8,100 avg volume, 15 days are for Cumberland Pharmaceuticals Incorporated (NASDAQ:CPIX)’s short sellers to cover CPIX’s short positions. The SI to Cumberland Pharmaceuticals Incorporated’s float is 1.28%. The stock decreased 0.35% or $0.03 during the last trading session, reaching $7.08. About 8,135 shares traded. Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) has risen 42.27% since January 14, 2017 and is uptrending. It has outperformed by 25.57% the S&P500.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care and gastroenterology markets in the United States and internationally. The company has market cap of $111.50 million. It marketed products include Acetadote injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of H. pylori infection and duodenal ulcer disease; and Ethyol (amifostine) for injection to treat oncology patients. It currently has negative earnings. The companyÂ’s product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension.

Investors sentiment decreased to 0.64 in Q3 2017. Its down 0.36, from 1 in 2017Q2. It worsened, as 3 investors sold Cumberland Pharmaceuticals Inc. shares while 11 reduced holdings. 2 funds opened positions while 7 raised stakes. 4.14 million shares or 4.39% less from 4.33 million shares in 2017Q2 were reported. Cambridge Inv Rech Advisors Inc reported 0% stake. Ariel Invests Ltd Liability Co reported 0.07% in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). Renaissance Technologies Ltd Liability Corp has 316,005 shares. Invesco accumulated 50,764 shares. Ny State Common Retirement Fund holds 250,230 shares or 0% of its portfolio. Vanguard Gru owns 302,950 shares. Oakworth Capital has invested 0.01% of its portfolio in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). Delta Asset Mngmt Ltd Liability Tn has 12,000 shares for 0.01% of their portfolio. Nationwide Fund Advsr holds 0% or 3,851 shares. Blackrock invested in 393,890 shares. 230 are held by Mufg Americas Corporation. Morgan Stanley invested 0% in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). California Public Employees Retirement System holds 53,800 shares or 0% of its portfolio. Sei Investments invested 0% of its portfolio in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). The Massachusetts-based Acadian Asset Mgmt Ltd Com has invested 0% in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX).

Since August 7, 2017, it had 0 insider purchases, and 12 sales for $93.68 million activity. 15,642 shares were sold by Riccio Daniel J., worth $2.42 million on Thursday, October 5. $8.79M worth of Apple Inc. (NASDAQ:AAPL) shares were sold by SCHILLER PHILIP W. LEVINSON ARTHUR D had sold 35,000 shares worth $5.52M. Shares for $9.98M were sold by FEDERIGHI CRAIG on Monday, August 7. Srouji Johny also sold $1.70M worth of Apple Inc. (NASDAQ:AAPL) shares. COOK TIMOTHY D sold $43.15M worth of stock. 31,625 Apple Inc. (NASDAQ:AAPL) shares with value of $5.00M were sold by SEWELL D BRUCE.

Analysts await Apple Inc. (NASDAQ:AAPL) to report earnings on January, 30. They expect $3.75 earnings per share, up 11.61% or $0.39 from last year’s $3.36 per share. AAPL’s profit will be $19.08 billion for 11.81 P/E if the $3.75 EPS becomes a reality. After $2.07 actual earnings per share reported by Apple Inc. for the previous quarter, Wall Street now forecasts 81.16% EPS growth.

Among 52 analysts covering Apple Inc. (NASDAQ:AAPL), 40 have Buy rating, 1 Sell and 11 Hold. Therefore 77% are positive. Apple Inc. had 344 analyst reports since July 21, 2015 according to SRatingsIntel. On Friday, July 21 the stock rating was maintained by Mizuho with “Hold”. The rating was maintained by Cowen & Co with “Market Perform” on Tuesday, December 22. The stock of Apple Inc. (NASDAQ:AAPL) has “Buy” rating given on Wednesday, October 12 by Goldman Sachs. BTIG Research maintained the shares of AAPL in report on Wednesday, March 1 with “Buy” rating. The rating was maintained by FBR Capital on Friday, August 7 with “Buy”. Maxim Group maintained Apple Inc. (NASDAQ:AAPL) on Thursday, September 14 with “Buy” rating. UBS maintained it with “Buy” rating and $115 target in Tuesday, July 26 report. On Tuesday, June 13 the stock rating was upgraded by Morgan Stanley to “Buy”. The firm has “Overweight” rating by Piper Jaffray given on Wednesday, April 27. Morgan Stanley maintained the shares of AAPL in report on Wednesday, October 26 with “Overweight” rating.

Investors sentiment increased to 0.7 in Q3 2017. Its up 0.02, from 0.68 in 2017Q2. It improved, as 52 investors sold AAPL shares while 1034 reduced holdings. 116 funds opened positions while 640 raised stakes. 2.97 billion shares or 2.78% less from 3.06 billion shares in 2017Q2 were reported. Aristotle Management Ltd Co invested in 0% or 4,000 shares. Oak Ridge Ltd has 2.09% invested in Apple Inc. (NASDAQ:AAPL) for 333,764 shares. Comerica Secs Incorporated accumulated 32,059 shares or 0.68% of the stock. Clarkston Cap Prns Ltd Liability Co invested in 9,193 shares. Cibc Financial Bank Usa has 1.19% invested in Apple Inc. (NASDAQ:AAPL) for 59,153 shares. Lehman Financial Inc stated it has 9,038 shares. Fmr Limited Liability Com stated it has 2.71% in Apple Inc. (NASDAQ:AAPL). Centurylink Invest Management Company reported 3.18% in Apple Inc. (NASDAQ:AAPL). Villere St Denis J Com Ltd Liability Com reported 0.55% in Apple Inc. (NASDAQ:AAPL). 52,207 were reported by Northern Mgmt Limited Liability Co. Hemenway Trust Limited Liability has invested 3.97% in Apple Inc. (NASDAQ:AAPL). Burgundy Asset Ltd owns 1.55% invested in Apple Inc. (NASDAQ:AAPL) for 1.06 million shares. Baker Ellis Asset Mngmt Limited reported 0.69% in Apple Inc. (NASDAQ:AAPL). Bbr Ltd Liability Corp invested in 10,249 shares or 0.34% of the stock. Highstreet Asset Mgmt reported 0.58% of its portfolio in Apple Inc. (NASDAQ:AAPL).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>